Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today that it has agreed to sell, by way of an underwritten public offering, 10,905,000 of its ordinary shares at a price of
$10.09 per share. The gross proceeds from the offering, before deducting the underwriting
discount and offering expenses, are expected to be approximately $110 million. The offering is
expected to close on October 12, 2022, subject to customary closing conditions.